**Biomaterials & Microfluidics Core Facility**

**2020 SECOND INTERNAL CALL OF PROPOSAL**

**ACCESS TO EMULATE™ ORGAN-ON-CHIP TECHNOLOGY**

**APPLICATION FORM**

3 pages (Police size 11) max., excluding tables & figures

Form sent the (date): DD/MM/YYYY

Completed application forms to be submitted at: [OOC@pasteur.fr](mailto:OOC@pasteur.fr)

We will acknowledge the receipt of all the applications

|  |
| --- |
| **Project Title / Acronym (if applicable)** |
|  |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Principal Investigator/Main Applicants** | | | | | | |
| Title: |  | First name: | |  | Surname: |  |
| Emai: |  | | | | | |
| Division / Department: | | |  | | | |
| Institut Pasteur/IPIN | | |  | | | |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Co- Investigators/Co -Applicants (add additional boxes as needed)** | | | | | | |
| Title: |  | First name: | |  | Surname: |  |
| Email: |  | | | | | |
| Division / Department: | | |  | | | |
| Institut Pasteur/IPIN/Others | | |  | | | |

1. **Project description** (3 pages maximum ; police size 11)
   1. Describe the research topic/background, objectives and hypothesis
   2. Outline work plan per work package (if more than one) in a table or scheme, including: time schedule (taking account that the experimental part of the project has to be completed before April 2021), milestones and deliverables. Indicate the role and responsibilities of the applicants in the activities.
   3. Stress the added value of the use of the OOC technology to the project: could the research question(s) be answered with existing data and a therefore suitable research methodology? If not, or only partially, please explain the added value of the use of the OOC technology to the project
   4. Stress the Potential to provide groundwork for future valorization and research funding

|  |  |
| --- | --- |
| Chip numbers required: |  |

1. **Publications:**

Recent publications related to the project (max 3 per team)

1. **Regulatory and Biosafety**
   1. **Will the project involve experiments with human/patient material?**

If yes, project leader has to make sure all regulation processes are fill in to obtain agreement from regulatory authorities, at the start of the project. In that regard, IP-CRT is providing support at  [crt-opendesk@pasteur.fr](mailto:crt-opendesk@pasteur.fr) and/or you can contact directly [crt@pasteur.fr](mailto:crt@pasteur.fr)

|  |  |
| --- | --- |
|  | **Answer** |
| 1. Use of healthy volunteers? | yes/no |
| 1. Use of patients? | yes/no |
| 1. Number of healthy volunteers |  |
| 1. Number of patients |  |
| 1. Is ethical approval from a commission needed regarding experimental subjects? | yes/no/NA |
| 1. If ‘e’ is answered with ‘yes’: Do you already have ethical approval from a commission to perform the study? | yes/no/requested/NA |

* 1. **Will the project involve any Highly Microbial Toxins (MOT)?**

|  |  |  |  |
| --- | --- | --- | --- |
| Yes |  | No |  |

* 1. **Which laboratory biosafety level is needed to carried out experiments? (Levels P2/P3)**

1. **Of note**

* Any submitted project will be examined IP-Organ-on Chips selection committee, which may approve or refuse it, within a 21 days’ period.
* The project leader commits to complete the experimental part of the project before April 2021.
* If collaboration in the framework of the project, external partners need to be exclusively from academia
* At the end of the project, you’ll be asked to provide a short report on data issued with the technology